P2, N=20, Active, not recruiting, Duke University | N=72 --> 20 | Trial completion date: Aug 2026 --> Jan 2026 | Trial primary completion date: Jul 2026 --> Jan 2026 | Recruiting --> Active, not recruiting

P3, N=120, Recruiting, Boehringer Ingelheim | Not yet recruiting --> Recruiting

Our results demonstrate that dapagliflozin not only enhances the antitumor efficacy of sunitinib against renal cell carcinoma but also alleviates sunitinib-induced cardiac toxicity in mice via modulation of the AMPKα-PPARα axis.

P3, N=420, Not yet recruiting, University of Cologne

P3, N=600, Recruiting, Assistance Publique - Hôpitaux de Paris | Not yet recruiting --> Recruiting | Trial completion date: Oct 2028 --> Jan 2029 | Initiation date: Sep 2025 --> Dec 2025 | Trial primary completion date: Oct 2028 --> Jan 2029

P2, N=10, Terminated, Jinling Hospital, China | N=100 --> 10 | Trial completion date: Dec 2027 --> Oct 2025 | Recruiting --> Terminated | Trial primary completion date: Jan 2027 --> Oct 2025; The patient enrollment rate is proceeding too slowly

P4, N=40, Not yet recruiting, University of Minnesota | Initiation date: Dec 2025 --> Mar 2026

P2, N=130, Not yet recruiting, Yale University

P3, N=300, Active, not recruiting, Kirby Institute | Recruiting --> Active, not recruiting

P=N/A, N=200, Not yet recruiting, Shanghai Chest Hospital

DAPA exerts protective effects against CIS-induced ovarian damage by modulating proliferation, cellular stress, inflammation, and apoptotic pathways, as evidenced by the downregulation of PCNA, HSP-70, KISS-1, TNF-α, and CAS-3, and upregulation of NRF2 and HO-1. These findings suggest that DAPA may offer a novel therapeutic approach for preserving ovarian function in patients undergoing chemotherapy.

P3, N=1750, Enrolling by invitation, University Medical Center Groningen | Trial completion date: Jan 2027 --> Jul 2027 | Trial primary completion date: Jan 2027 --> Jul 2027